Goldline Pharmaceutical IPO

The price band is ₹41-43 per share with a lot size of 3000 shares. Minimum investment: ₹129000.

Goldline Pharmaceutical Limited is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand. The company operates through five product segments: Goldline Pharma, Goldline Cardinal, Goldline Aayushman, Goldline InLife, and Goldline Wellness, catering to therapeutic areas including cardiology, diabetology, orthopaedics, paediatrics, gastroenterology, neurology, critical care, and oncology supportive care. Its products are manufactured through contractual arrangements with third-party manufacturers based on the company’s specifications, demand analysis, and market research. Goldline also provides material supply and procurement support services to hospitals and healthcare partners through promoter group entities involved in trading and supply chain operations. The company markets its products through a distribution network consisting of distributors, wholesalers, and retailers. As of March 31, 2025, Goldline maintained contractual arrangements with 15 manufacturers and seven distributors to support its supply chain and operations. Use of proceeds: This is a fresh issue of shares. Therefore, the net proceeds from the fresh issue will go to the company. They will be utilised for the following purposes: Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company — Rs 8.9 crore General corporate purposes

Review the IPO's fundamentals, financials, and market conditions carefully. Always do your own research before investing.

Goldline Pharmaceutical was founded by Mr Amol Mujumdar in 2004.